PH12015500071A1 - Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia - Google Patents

Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Info

Publication number
PH12015500071A1
PH12015500071A1 PH12015500071A PH12015500071A PH12015500071A1 PH 12015500071 A1 PH12015500071 A1 PH 12015500071A1 PH 12015500071 A PH12015500071 A PH 12015500071A PH 12015500071 A PH12015500071 A PH 12015500071A PH 12015500071 A1 PH12015500071 A1 PH 12015500071A1
Authority
PH
Philippines
Prior art keywords
hyperkalemia
treatment
zirconium silicate
calcium
microporous zirconium
Prior art date
Application number
PH12015500071A
Other languages
English (en)
Inventor
Keyser Donald Jeffrey
Alvaro F Guillem
Original Assignee
Zs Pharma Inc
Keyser Donald Jeffrey
Alvaro F Guillem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zs Pharma Inc, Keyser Donald Jeffrey, Alvaro F Guillem filed Critical Zs Pharma Inc
Publication of PH12015500071A1 publication Critical patent/PH12015500071A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0006—Controlling or regulating processes
    • B01J19/0013—Controlling the temperature of the process
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/006—Baffles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/0066—Stirrers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/18—Stationary reactors having moving elements inside
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/025—Silicon compounds without C-silicon linkages
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00054—Controlling or regulating the heat exchange system
    • B01J2219/00056—Controlling or regulating the heat exchange system involving measured parameters
    • B01J2219/00058—Temperature measurement
    • B01J2219/00063—Temperature measurement of the reactants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00074—Controlling the temperature by indirect heating or cooling employing heat exchange fluids
    • B01J2219/00087—Controlling the temperature by indirect heating or cooling employing heat exchange fluids with heat exchange elements outside the reactor
    • B01J2219/00094—Jackets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00761—Details of the reactor
    • B01J2219/00763—Baffles
    • B01J2219/00765—Baffles attached to the reactor wall
    • B01J2219/00768—Baffles attached to the reactor wall vertical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Geology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
PH12015500071A 2012-07-11 2015-01-12 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia PH12015500071A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670415P 2012-07-11 2012-07-11
US201361800291P 2013-03-15 2013-03-15
PCT/US2013/050071 WO2014011876A2 (en) 2012-07-11 2013-07-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Publications (1)

Publication Number Publication Date
PH12015500071A1 true PH12015500071A1 (en) 2015-03-16

Family

ID=49916686

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015500071A PH12015500071A1 (en) 2012-07-11 2015-01-12 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Country Status (16)

Country Link
US (1) US9707255B2 (en:Method)
EP (1) EP2872148A4 (en:Method)
JP (1) JP2015529640A (en:Method)
KR (1) KR20150036555A (en:Method)
CN (1) CN104968336A (en:Method)
AU (1) AU2013290141A1 (en:Method)
BR (1) BR112015000636A2 (en:Method)
CA (1) CA2878832A1 (en:Method)
CL (1) CL2015000078A1 (en:Method)
CO (1) CO7200258A2 (en:Method)
HK (2) HK1209029A1 (en:Method)
IL (1) IL236655A0 (en:Method)
IN (1) IN2015KN00201A (en:Method)
MX (1) MX2015000381A (en:Method)
PH (1) PH12015500071A1 (en:Method)
WO (1) WO2014011876A2 (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2673237T3 (pl) 2011-02-11 2019-04-30 Zs Pharma Inc Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
CN104968336A (zh) 2012-07-11 2015-10-07 Zs制药公司 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
US20140302175A1 (en) * 2013-04-05 2014-10-09 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
US20160038538A1 (en) * 2013-11-08 2016-02-11 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
EP4378577A3 (en) * 2013-11-08 2024-10-23 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
US11964266B2 (en) 2019-07-09 2024-04-23 Uop Llc Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) 2019-07-09 2022-11-01 Uop Llc Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
US11577014B2 (en) 2019-07-09 2023-02-14 Uop Llc Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統
US12036528B2 (en) 2020-09-30 2024-07-16 Uop Llc Process for removing lead ions from boldily fluids using metallate ion exchange compositions
CN119643609A (zh) * 2025-02-17 2025-03-18 北京华睿鼎信科技有限公司 一种晶相杂质的分析方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329480A (en) 1963-10-18 1967-07-04 Union Oil Co Crystalline zircono-silicate zeolites
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US3959445A (en) * 1973-04-30 1976-05-25 E. I. Du Pont De Nemours And Company Highly absorbent, low bulk density sodium silicate
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
LU84743A1 (fr) * 1983-04-11 1984-11-28 Sipac Procede de fabrication de zeolite a et produits obtenus
US4943545A (en) 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5032556A (en) 1989-02-21 1991-07-16 Tosoh Corporation Preparation method for zircon powder
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
JP3265344B2 (ja) 1990-03-16 2002-03-11 東ソー株式会社 ジルコン粉末の合成法
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
JP2971946B2 (ja) 1992-10-28 1999-11-08 クロスフィールド・リミテッド シリカ
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
GB9601398D0 (en) 1996-01-24 1996-03-27 Piper Edwina M Composition
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
CA2214495C (en) 1996-09-25 2002-02-05 Daniel L. Woodard Hydrated zirconium silicate composition for purification of nucleic acids
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) * 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
EP0982785A4 (en) 1997-05-12 2001-04-18 Japan Represented By Director SEPARATOR FOR ACCUMULATOR AND ALKALI ELECTRIC ACCUMULATOR USING THE SAME
JPH11292769A (ja) * 1998-04-10 1999-10-26 Toyo Seiyaku Kasei Kk 高カリウム血症改善剤組成物
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US5989518A (en) * 1998-12-29 1999-11-23 Uop Llc Process for synthesizing and controlling the particle size and particle size distribution of a molecular sieve
EP1038580B1 (en) * 1999-03-26 2005-05-25 Uop Llc Ammonium ion adsorption process using zirconium silicate and zirconium germanate molecular sieves
US6332985B1 (en) * 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
JP2004149525A (ja) * 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CN1894029B (zh) 2003-12-15 2011-05-11 旭化成化学株式会社 多孔成形物及其生产方法
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
JP5000480B2 (ja) * 2004-03-30 2012-08-15 レリプサ， インコーポレイテッド イオンバランス異常の治療の方法および組成物
WO2006071532A1 (en) 2004-12-28 2006-07-06 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
WO2006134915A1 (ja) 2005-06-14 2006-12-21 Asahi Kasei Chemicals Corporation 水処理装置及び水処理方法
CA2624170C (en) 2005-09-30 2014-02-25 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
JP2009510233A (ja) * 2005-09-30 2009-03-12 レリプサ， インコーポレイテッド 架橋シェルを有するコア−シェルコンポジットを製造する方法および該方法によって生じたコア−シェルコンポジット
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
US20080292695A1 (en) 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008082087A1 (en) 2007-01-03 2008-07-10 Insilicotech Co., Ltd Coordination polymer crystal with porous metal-organic frameworks and preperation method thereof
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
JP5583606B2 (ja) 2008-02-26 2014-09-03 コーニング インコーポレイテッド ケイ酸塩ガラス用の清澄剤
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
PL2673237T3 (pl) 2011-02-11 2019-04-30 Zs Pharma Inc Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
JP5982469B2 (ja) 2011-04-08 2016-08-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ アシル化触媒の製造方法
US10092688B2 (en) 2011-05-13 2018-10-09 Laura Jean Robinson Medicament kit and method of use
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
EP2812281B1 (en) 2012-02-06 2020-07-29 Basf Se Iron- and copper-containing zeolite beta from organotemplate-free synthesis and use thereof in the selective catalytic reduction of nox
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
CN104968336A (zh) 2012-07-11 2015-10-07 Zs制药公司 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
DK2882444T3 (da) 2012-10-22 2025-11-03 Zs Pharma Inc Mikroporøs zirconiumsilikat til behandling af hyperkaliæmi

Also Published As

Publication number Publication date
CN104968336A (zh) 2015-10-07
CO7200258A2 (es) 2015-02-27
WO2014011876A3 (en) 2015-07-16
EP2872148A2 (en) 2015-05-20
CL2015000078A1 (es) 2015-06-05
HK1209029A1 (en) 2016-03-24
BR112015000636A2 (pt) 2017-08-08
US20140105971A1 (en) 2014-04-17
EP2872148A4 (en) 2016-06-15
KR20150036555A (ko) 2015-04-07
AU2013290141A1 (en) 2015-02-05
JP2015529640A (ja) 2015-10-08
WO2014011876A2 (en) 2014-01-16
IL236655A0 (en) 2015-02-26
IN2015KN00201A (en:Method) 2015-06-12
CA2878832A1 (en) 2014-01-16
MX2015000381A (es) 2015-11-23
US9707255B2 (en) 2017-07-18
HK1215861A1 (zh) 2016-09-23

Similar Documents

Publication Publication Date Title
PH12015500071A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
PH12015500849A1 (en) Microporous zirconium silicate for treating hyperkalemia
PH12013501762B1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2019001414A (es) Angiogenesis utilizando celulas madre placentarias.
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
MY161088A (en) Agonists of gpr40
MX394137B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
MX2013004061A (es) Analogos de ciclosporina.
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
WO2012065102A8 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
PH12016500864A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
MX2016016756A (es) Terapia con células madre en patologías endometriales.
MX2013004062A (es) Analogos de ciclosporina.
PH12016500861A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
EA201400828A1 (ru) Фармацевтическая композиция в качестве субстанции антирефлюксного антацидного препарата
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GB201120259D0 (en) Allogeneic immune response control
PH12016501119A1 (en) Zirconium silicate for treating hyperkalemia without co-administering lithium
EA201591521A1 (ru) Композиция, содержащая арабиногалактан и полифенолы из лиственницы
GB2553686A8 (en) Ethynylxanthines, preparation and use as calcium ion channel modulators